Carregando...
Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats
The hypoglycaemic target of empagliflozin (EMP), as a novel inhibitor of sodium-glucose cotransporter (SGLT2), is clear. However, recent studies have shown that EMP also has an important role in lipid metabolism and cardiovascular diseases. The liver plays an important role in the development of typ...
Na minha lista:
| Publicado no: | Front Endocrinol (Lausanne) |
|---|---|
| Principais autores: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7092631/ https://ncbi.nlm.nih.gov/pubmed/32256445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2020.00111 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|